Liraglutide and a Calorie Restricted Diet Augments Weight Loss and Decreases Risk of Type 2 Diabetes and CVD.
NCT01784965 on ClinicalTrials.gov · last registry update 2017-04-21
A small phase 3 — 69 participants, against a typical 424. The sponsor logged completion for December 2012. Primary outcome, as filed: Change in Weight Reported at 14 Weeks. liraglutide is approved in the US, but not for prediabetes — a registration here is not an approval, and most drugs tested in a new condition never get one for it.
- Status
- COMPLETED
- Phase
- P3
- Drug
- liraglutideSaxenda, Victoza, Xultophy
- Sponsor
- Stanford University
- Sponsor type
- Other
- Enrollment
- 69
- Started
- 2009-12
- Primary completion
- 2012-12 actual
Observed history
No changes recorded since monitoring began on 2026-08-21. This record has held steady. If a reporting date moves, a status changes or enrollment is resized, it will appear here with the previous value alongside the new one.
Primary outcome
Change in Weight Reported at 14 Weeks
Conditions studied
Pre-diabetes · Older Adults
Every field above is taken directly from the registry record. See all detected changes across the class, or the liraglutide page for this molecule’s full trial and approval history.